Abstract
Heart transplantation is the treatment of choice for patients with refractory heart failure treatment. Although there were advances in medical therapy and immunological knowledge regarding rejection, it is one of the major limitations for long-term survival for those who were submitted to heart transplantation. In this chapter, the main issues of rejection and prevention in heart transplantation will be discussed.
Reference10 articles.
1. Daly K. Contemporary transplantation immunosuppression: Balancing on the immunosuppression seesaw. In: Canter C, Everitt E, Burch M, Louis JD, editors. Pediatric Heart Transplantation. Kirklin KJ, series editor. ISHLT Monograph Series. Chicago, IL: ISHLT; 2019. pp. 52-93
2. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. The Journal of Heart and Lung Transplantation. 2023;42(5):e1-e141
3. Colvin MM, Cook JL, Chang PM et al. Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639. Available from: http://circ.ahajournals.org/
4. Rao RA, Kransdorf EP, Patel JK, et al. How to approach HLA sensitization in heart transplant candidates. JACC: Heart Failure. 2023;11(4):469-475
5. Lefaucheur C, Louis K, Morris AB, STAR 2022 Working Group, et al. Clinical recommendations for posttransplant assessment of anti-HLA (human leukocyte antigen) donor-specific antibodies: A sensitization in transplantation: Assessment of risk consensus document. American Journal of Transplantation. 2023;23(1):115-132